

# Enhanced self-efficacy for HCV management among people participating in a HCV education program focused on drug and alcohol and primary care settings

Emma Day<sup>1</sup>, Nikitah Habraken<sup>1</sup>, Heather Valerio<sup>2</sup>, Laina Runk<sup>1</sup>, Andrew Lloyd<sup>2</sup>, Alessio Aghemo<sup>3</sup>, Olivia Dawson<sup>1</sup>, John Dillon<sup>4</sup>, Karine Lacombe<sup>5</sup>, Jeffrey V Lazarus<sup>6</sup>, Rui Tato Marinho<sup>7</sup>, Alberto Moriggia<sup>8</sup>, Anne Øvrehus<sup>9</sup>, Jens Reimer<sup>10</sup>, Hemant Shah<sup>11</sup>, Marta Torrens<sup>12</sup>, and Jason Grebely<sup>2</sup>

<sup>1</sup>Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, Australia; <sup>2</sup>The Kirby Institute, UNSW Sydney; Australia <sup>3</sup>Humanitas University, Italy; <sup>4</sup>University of Dundee, Ninewells Hospital and Medical School, Scotland; <sup>5</sup>University Hospital Saint-Antoine, France; <sup>6</sup>Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Spain; <sup>7</sup>Santa Maria Hospital, Universidade de Lisboa, Portugal; <sup>8</sup>Fondazione Epatocentro Ticino, Switzerland; <sup>9</sup>Odense University Hospital, Denmark; <sup>10</sup>Bremen Hospital Group, Germany; <sup>11</sup>Francis Family Liver Clinic, University of Toronto, Canada; <sup>12</sup>Department of Psychiatry, Universitat Autònoma de Barcelona, Spain



# Disclosures

*The development and delivery of the Education Program have been funded by AbbVie Inc., Gilead Sciences, Inc., Merck Sharp & Dohme Corp., and Mundipharma International Ltd.*

*Sponsorship is governed by INHSU and ASHM's Sponsorship Policies and the sponsor has no control over content, tone, emphasis, allocation of funds or selection of recipients. INHSU and ASHM do not endorse or promote any sponsor's product or service.*

# About the Education Program

## Goals

- ① To enhance education and training on management of hepatitis C in primary care and drug and alcohol settings
- ① To partner with international colleagues and organisations to deliver education globally
- ① To enhance in-country capacity to continue to deliver training
- ① To ultimately increase HCV testing and treatment in primary care and drug and alcohol settings

## Target audience

- ① Healthcare practitioners working in primary care or in drug and alcohol settings

# Hepatitis C in Primary Care and Drug and Alcohol Settings Education Program

## Part 1



### Online Module

Epidemiology  
Testing  
Treatment  
Monitoring

## Part 2



### Face-face Workshop

Full-day  
Interactive case studies  
Facilitated by local experts

## Part 3




### Tailored Toolkit

Resources for the local  
area to enable practical  
application of learning

**Aim:** to evaluate changes in self-efficacy for HCV management among attendees participating in an HCV education program focused on primary care and drug and alcohol settings.

# Delivery Locations


## International Roll-out



- Belgium
- Canada
- Spain
- Switzerland
- UK
- France
- Portugal
- Australia
- Germany (2020)
- Italy (2020)
- Sweden (2020)


# Delivery Locations

International Roll-out




- **Belgium**
- **Canada**
- **Spain**
- **Switzerland**
- **UK**
- **France**
- **Portugal**
- **Australia**
- **Germany (2020)**
- **Italy (2020)**
- **Sweden (2020)**

# Attendee Demographics




Profession



Service setting

# Methods

**Online  
Surveys**




**Key  
Measures**

- Demographics
- Practice change
- Knowledge change
- Attitude change
- Confidence change across core competencies
- Learning objectives



# Confidence in Program Competencies (n=318; p<0.001)

**BEFORE** the workshops, less than half of participants who completed the surveys were reporting *confident or very confident and competent*.



**AFTER** the workshops, the majority of these participants reported to be *confident or very confident and competent*.

# Conclusions

- ① Self reported confidence related to HCV management and treatment improved following participation in the educational program
- ① Further work required to evaluate sustained impact of the education, including enhanced HCV testing and treatment

# Acknowledgements

- **Dr Alessio Aghemo**, Humanitas University
- **Prof. John Dillon**, University of Dundee
- **Prof. Karine Lacombe**, Saint-Antoine Hospital
- **Prof. Jeffrey Lazarus**, University of Barcelona
- **Prof. Rui Tato Marinho**, Hospital Santa Maria
- **Dr Alberto Moriggia**, Epatocentro Liver Clinic
- **Dr Anne Øvrehus**, Odense University Hospital
- **Prof. Jens Reimer**, University Medical Centre Hamburg
- **Prof. Geert Robaey**s, U Hasselt
- **Dr Hemant Shah**, University Health Network
- **Prof. Marta Torrens**, Hospital del Mar
- **Prof. Jason Grebely**, Kirby Institute
- **Prof. Greg Dore**, Kirby Institute
- **Prof. Andrew Lloyd**, Kirby Institute
- **Heather Valerio**, Kirby Institute
- **Emma Day**, ASHM
- **Olivia Dawson**, ASHM
- **Laina Runk**, ASHM
- **AbbVie Inc.**
- **Gilead Sciences Inc.**
- **Merck Sharp & Dohme Corp.**
- **Mundipharma International Ltd.**
- **All other partners and funders**